Investigational drug · Phase 3
HU-045
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glabellar Lines.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HU-045"
First trial start
2026
Sep 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HU-045", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glabellar Lines
Largest trials
Live from ClinicalTrials.gov: studies naming "HU-045" as an intervention, largest first.
- To Evaluate HU-045 With Moderate to Severe Glabellar LinesPivotal-lookingRecruiting
Huons BiopharmaIndustry
NCT07870694 · 390 participants (planned) · Start Sep 3, 2026 · Primary completion May 2027
Drug: HU-045; Xeomin® · For: Glabellar Lines
Sites: Seoul, South Korea
- To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)Pivotal-lookingStatus unknown
Huons BiopharmaIndustry
NCT06205797 · 312 participants (planned) · Start Jun 20, 2024 · Primary completion Nov 30, 2024
Drug: HU-045; Xeomin® · For: Glabellar Lines
Sites: Seoul, South Korea
- Phase 2 of HU-045 in Glabellar LinesCompleted
Huons Co., Ltd.Industry
NCT05298449 · 50 participants · Start Mar 28, 2022 · Primary completion Nov 7, 2022
Drug: HU-045; Xeomin® · For: Glabellar Lines
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- A phase I clinical trial to evaluate the safety of HU-045 for treating moderate-to-severe glabellar lines: a pilot study.
Han HS, Park JW, Yoo KH, et al. · J Eur Acad Dermatol Venereol 2021
Also in development for Glabellar Lines
- AGN-151586Phase 32 trials
AbbVie · Forehead Lines, Glabellar Lines
- JTM201Phase 21 trial
Jetema USA Inc. · Glabellar Lines
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.